In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MorphoSys nets $222mm through IPO on Nasdaq

Executive Summary

Public German biotech MorphoSys AG (antibody therapeutics and technologies) netted $222.3mm in its initial public offering on the Nasdaq Exchange of 9.545mm American Depositary Shares (including the overallotment) at $25.04. Since each ADS is equivalent to 0.25 of an ordinary share, this equates to 2.39mm ordinary shares at $100.16 apiece.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies